Literature DB >> 15710578

Thrombosis as a conformational disease.

Javier Corral1, Vicente Vicente, Robin W Carrell.   

Abstract

Conformational diseases are a newly recognized group of heterogeneous disorders resulting from the conformational instability of individual proteins. Such instability allows the formation of intermolecular linkages between b-sheets, to give protein aggregation and inclusion body formation. The serpin family of serine protease inhibitors provides the best-studied examples of the structural changes involved. Notably, mutations of a-1-antitrypsin result in its intracellular polymerization and accumulation in the liver leading eventually to cirrhosis. Here we consider how other conformational changes in another serpin, antithrombin, can cause its inactivation with consequent thrombosis. Thirteen different missense mutations in antithrombin are associated with either oligomer formation or with conversion of the active molecule into an inactive latent form. Each of these variant antithrombins is associated with an increased risk of thrombosis that typically occurs in an unexpectedly severe and sudden form. The trigger for this episodic thrombosis is believed to be the sudden conformational transition of the antithrombin with an accompanying loss of inhibitory activity. But what causes the transition? This is still unclear, though a likely contributor is the increased body temperature that occurs with infections hence the frequency of episodes associated with the urinary infections of pregnancy. The search for other causes is important, as the conformational perturbation of normal antithrombin is likely to be a contributory cause to the sporadic and apparently idiopathic occurrence of venous thrombosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15710578

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  12 in total

Review 1.  Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.

Authors:  Qudsia Rashid; Poonam Singh; Mohammad Abid; Mohamad Aman Jairajpuri
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

2.  L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases.

Authors:  David Hernández-Espinosa; Antonia Miñano; Constantino Martínez; Elena Pérez-Ceballos; Inmaculada Heras; José L Fuster; Vicente Vicente; Javier Corral
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

3.  Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation.

Authors:  Irene Martínez-Martínez; Adriana Ordóñez; José Navarro-Fernández; Angel Pérez-Lara; Ricardo Gutiérrez-Gallego; Rafael Giraldo; Constantino Martínez; Esther Llop; Vicente Vicente; Javier Corral
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

4.  The infective polymerization of conformationally unstable antithrombin mutants may play a role in the clinical severity of antithrombin deficiency.

Authors:  Irene Martínez-Martínez; José Navarro-Fernández; Sonia Aguila; Antonia Miñano; Nataliya Bohdan; María Eugenia De La Morena-Barrio; Adriana Ordóñez; Constantino Martínez; Vicente Vicente; Javier Corral
Journal:  Mol Med       Date:  2012-07-18       Impact factor: 6.354

5.  Functional consequences of the prothrombotic SERPINC1 rs2227589 polymorphism on antithrombin levels.

Authors:  Ana I Antón; Raúl Teruel; Javier Corral; Antonia Miñano; Irene Martínez-Martínez; Adriana Ordóñez; Vicente Vicente; Beatriz Sánchez-Vega
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

6.  Rare double heterozygous mutations in antithrombin underlie hereditary thrombophilia in a Chinese family.

Authors:  Haoyu Deng; Jiaquan Chen; Hui Xie; Yi Gu; Kai Yuan; Peng Wang; Wei Shen; Wei Liang; Hao Zhang; Jiwei Zhang; Jun Xie; Lan Zhang
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

7.  A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis.

Authors:  Javier Corral; Rocio González-Conejero; Jose Manuel Soria; Jose Ramón González-Porras; Elena Pérez-Ceballos; Ramón Lecumberri; Vanessa Roldán; Juan Carlos Souto; Antonia Miñano; David Hernández-Espinosa; Ignacio Alberca; Jordi Fontcuberta; Vicente Vicente
Journal:  Blood       Date:  2006-03-09       Impact factor: 22.113

8.  Antithrombin III deficiency in Indian patients with deep vein thrombosis: identification of first India based AT variants including a novel point mutation (T280A) that leads to aggregation.

Authors:  Teena Bhakuni; Amit Sharma; Qudsia Rashid; Charu Kapil; Renu Saxena; Manoranjan Mahapatra; Mohamad Aman Jairajpuri
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

9.  Transient desialylation in combination with a novel antithrombin deficiency causing a severe and recurrent thrombosis despite anticoagulation therapy.

Authors:  Nuria Revilla; María Eugenia de la Morena-Barrio; Antonia Miñano; Raquel López-Gálvez; Mara Toderici; José Padilla; Ángel García-Avello; María Luisa Lozano; Dirk J Lefeber; Javier Corral; Vicente Vicente
Journal:  Sci Rep       Date:  2017-03-17       Impact factor: 4.379

10.  Association of a Variant in VWA3A with Response to Anti-Vascular Endothelial Growth Factor Treatment in Neovascular AMD.

Authors:  Michelle Grunin; Gala Beykin; Elior Rahmani; Regev Schweiger; Gal Barel; Shira Hagbi-Levi; Sarah Elbaz-Hayoun; Batya Rinsky; Michal Ganiel; Shai Carmi; Eran Halperin; Itay Chowers
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-02-07       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.